- Home
- PHR
PHR
Phreesia Inc.
as 05-30-2025 10:41am EST
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $31.23 | AVG Volume (30 days): | 522.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.07 - $30.53 | Next Earning Date: | 05-28-2025 |
| Revenue: | $434,532,000 | Revenue Growth: | 16.29% |
| Revenue Growth (this year): | 14.55% | Revenue Growth (next year): | 11.89% |
Stock Insider Trading Activity of Phreesia Inc. (PHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Linetsky David | PHR | SVP, Life Sciences | Apr 21 '25 | Sell | $23.04 | 260 | $5,990.87 | 8,752 | |
| Hui Yvonne | PHR | Principal Accounting Officer | Apr 21 '25 | Sell | $23.37 | 2,323 | $54,401.51 | 23,922 | |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 16 '25 | Sell | $23.81 | 624 | $14,855.69 | 129,820 | |
| Roberts Evan | PHR | Chief Operating Officer | Apr 16 '25 | Sell | $23.81 | 1,845 | $43,924.28 | 774,807 | |
| Linetsky David | PHR | SVP, Life Sciences | Apr 16 '25 | Sell | $23.73 | 4,499 | $106,742.36 | 8,752 | |
| Hoffman Allison C | PHR | General Counsel & Secretary | Apr 16 '25 | Sell | $23.81 | 1,213 | $28,878.13 | 137,921 | |
| Indig Chaim | PHR | Chief Executive Officer | Apr 16 '25 | Sell | $23.81 | 3,091 | $73,588.06 | 1,254,574 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Apr 16 '25 | Sell | $23.81 | 864 | $20,569.42 | 107,547 | |
| Hui Yvonne | PHR | Principal Accounting Officer | Apr 15 '25 | Sell | $23.85 | 732 | $17,439.44 | 23,922 | |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Apr 8 '25 | Sell | $23.97 | 1,695 | $40,430.27 | 129,820 |
Latest Phreesia Inc. News
PHR Breaking Stock News: Dive into PHR Ticker-Specific Updates for Smart Investing
StockStory
11 hours ago
Healthcare Technology Stocks Q1 Recap: Benchmarking GoodRx (NASDAQ:GDRX)
StockStory
11 hours ago
Q1 Earnings Outperformers: Phreesia (NYSE:PHR) And The Rest Of The Healthcare Technology for Providers Stocks
TipRanks
a day ago
Morning Movers: Abercrombie & Fitch skyrockets following first quarter results
MT Newswires
a day ago
Truist Lifts Price Target on Phreesia to $35 From $34, Keeps Buy Rating
GuruFocus.com
a day ago
Phreesia Inc (PHR) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ...
StockStory
2 days ago
PHR Q1 Earnings Call: Revenue Misses, Profitability Surges Amid Product Expansion
Zacks
2 days ago
Here's What Key Metrics Tell Us About Phreesia (PHR) Q1 Earnings
MT Newswires
2 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday.
Compare PHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHR Phreesia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.